Literature DB >> 6232895

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

N X Chin, H C Neu.   

Abstract

The in vitro activity of ciprofloxacin, a quinolone-carboxylic acid derivative, was compared with those of norfloxacin, cefotaxime, cephalexin, ceftazidime, moxalactam, amoxicillin, and methicillin and other agents, as appropriate. The MICs of ciprofloxacin for 90% of members of the family Enterobacteriaceae and for Pseudomonas aeruginosa, Neisseria spp., and Bacteroides fragilis were between 0.005 and 0.8 micrograms/ml, whereas streptococci and staphylococci were all inhibited by less than or equal to 6.3 micrograms/ml. Ciprofloxacin was 4- to 32-fold more active than norfloxacin and inhibited gentamicin-, ameikacin-, cefotaxime-, and moxalactam-resistant members of the family Enterobacteriaceae and P. aeruginosa and methicillin-resistant Staphylococcus aureus. The activity of ciprofloxacin was not affected by serum but decreased in the presence of acid urine. The frequency of resistance to ciprofloxacin was between 10(-7) and 10(-9).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232895      PMCID: PMC185508          DOI: 10.1128/AAC.25.3.319

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

2.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

4.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.

Authors:  J H Tenney; R W Maack; G R Chippendale
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  6 in total
  128 in total

1.  In vitro antibiotic resistance in bacterial keratitis in London.

Authors:  S J Tuft; M Matheson
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  J Hosp Infect       Date:  2010-12       Impact factor: 3.926

4.  Coumarin and quinolone action in archaebacteria: evidence for the presence of a DNA gyrase-like enzyme.

Authors:  M Sioud; O Possot; C Elie; L Sibold; P Forterre
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

5.  Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus.

Authors:  K Ubukata; N Itoh-Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Ciprofloxacin concentration in the rabbit aqueous humor and vitreous following intravenous and subconjunctival administration.

Authors:  W Behrens-Baumann; J Martell
Journal:  Infection       Date:  1988       Impact factor: 3.553

7.  In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.

Authors:  A G Arguedas; J C Akaniro; H R Stutman; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

8.  Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.

Authors:  R E Roddy; H H Handsfield; E W Hook
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 9.  Protein binding: do we ever learn?

Authors:  Markus A Zeitlinger; Hartmut Derendorf; Johan W Mouton; Otto Cars; William A Craig; David Andes; Ursula Theuretzbacher
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 10.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.